165 related articles for article (PubMed ID: 34158588)
1. A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma.
Foley KG; Lavery A; Napier E; Campbell D; Eatock MM; Kennedy RD; Bradley KM; Turkington RC
Sci Rep; 2021 Jun; 11(1):13061. PubMed ID: 34158588
[TBL] [Abstract][Full Text] [Related]
2. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC; Knight LA; Blayney JK; Secrier M; Douglas R; Parkes EE; Sutton EK; Stevenson L; McManus D; Halliday S; McCavigan AM; Logan GE; Walker SM; Steele CJ; Perner J; Bornschein J; MacRae S; Miremadi A; McCarron E; McQuaid S; Arthur K; James JA; Eatock MM; O'Neill R; Noble F; Underwood TJ; Harkin DP; Salto-Tellez M; Fitzgerald RC; Kennedy RD;
Gut; 2019 Nov; 68(11):1918-1927. PubMed ID: 30852560
[TBL] [Abstract][Full Text] [Related]
3. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
[TBL] [Abstract][Full Text] [Related]
4. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
[TBL] [Abstract][Full Text] [Related]
5. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Role of Pre-operative Positron Emission Tomography-Computed Tomography and Endoscopic Ultrasound Parameters in Oesophageal Adenocarcinoma.
Dellaportas D; Zylstra J; Gossage J; Baker C; Kelly M; Hemelrijck MV; Griffin N; Lagergren J; Davies AR
Chirurgia (Bucur); 2019; 114(4):443-450. PubMed ID: 31511130
[No Abstract] [Full Text] [Related]
8. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
9. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.
Tamandl D; Gore RM; Fueger B; Kinsperger P; Hejna M; Paireder M; Haug A; Schoppmann SF; Ba-Ssalamah A
Eur Radiol; 2016 Feb; 26(2):311-21. PubMed ID: 26040648
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of standardized uptake value on preoperative ¹⁸F-FDG PET/CT in patients with ampullary adenocarcinoma.
Choi HJ; Kang CM; Jo K; Lee WJ; Lee JH; Ryu YH; Lee JD
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):841-7. PubMed ID: 25216749
[TBL] [Abstract][Full Text] [Related]
11. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
[TBL] [Abstract][Full Text] [Related]
12. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
13. Response rate and diagnostic accuracy of early PET-CT during neo-adjuvant therapies in oesophageal adenocarcinoma: A systematic review and meta-analysis.
Foley KG; Jeffries J; Hannon C; Coles B; Bradley KM; Smyth E
Int J Clin Pract; 2021 Jun; 75(6):e13906. PubMed ID: 33300222
[TBL] [Abstract][Full Text] [Related]
14. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
[TBL] [Abstract][Full Text] [Related]
15. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma.
Chhabra A; Ong LT; Kuk D; Ku G; Ilson D; Janjigian YY; Wu A; Schöder H; Goodman KA
Br J Cancer; 2015 Dec; 113(12):1658-65. PubMed ID: 26657654
[TBL] [Abstract][Full Text] [Related]
17. Radiological prediction of positive circumferential resection margin in oesophageal cancer.
Foley KG; Christian A; Patel N; Lewis WG; Roberts SA
Eur J Radiol; 2018 Oct; 107():119-124. PubMed ID: 30292255
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Sole CV; Calvo FA; Alvarez E; Peligros I; Garcia-Alfonso P; Ferrer C; Ochoa E; Herranz R; Carreras JL
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1635-44. PubMed ID: 23801169
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer.
Song BI; Kim HW; Won KS; Ryu SW; Sohn SS; Kang YN
Medicine (Baltimore); 2015 Jul; 94(26):e1037. PubMed ID: 26131811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
